Skip to main navigation
Pharvaris N.V. Logo
  • Careers
  • Investors & Media
  • Contact
  • SCIENCE
  • PIPELINE
  • DISEASE FOCUS
  • HAE COMMUNITY
  • CLINICAL TRIALS
  • ABOUT US

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

CHAPTER-1 Phase 2 Top-line Data

Dec 6, 2023 8:00 AM EST

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks 177 KB
CHAPTER-1 Phase 2 Top-line Data Presentation 1.3 MB
Click for Webcast 19.5 MB
Pharvaris N.V. Logo

CONTACT US

FOLLOW US

linkedin logo Facebook icon

©2026 Pharvaris N.V. © All Rights Reserved

  • Privacy Policy
  • Clinical Trial Privacy Notice
  • Global Privacy Laws
  • Terms of Use